reports
Prelude Therapeutics Reports First Quarter 2024 Financial Results and ...
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 New preclinical data presented at AACR 2024 included first characterization of PRT7732, a highly-selective, orally bioavailable SMARCA2 degrader Operational leadership capabilities further strengthened by recent hires Chief Business Officer Sean Brusky and Senior Vice President, Investor Relations Robert Doody Current cash runway ...
First Watch Restaurant Group, Inc. Reports Strong Q1 2024 Financial Re...
First Watch Restaurant Group, Inc. Reports Strong Q1 2024 Financial Results Total revenues increased 14.7%; same-restaurant sales growth of 0.5%*Income from operations margin of 5.1% and restaurant level operating profit margin of 20.8%Net income of $7.2 million and Adjusted EBITDA of $28.6 million9 system-wide restaurants opened across 8 states BRADENTON, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today reported financial results for...
BioCryst to Present at Upcoming Investor Conferences
BioCryst to Present at Upcoming Investor Conferences RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will present at the following conferences: Citizens JMP Life Sciences Conference in New York on Monday, May 13, 2024, at 12:30 p.m. ET. 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 2024, at 3:05 p.m. ET. Bank of America Health Care Conference 2024 in Las Vegas on Wednesday, May 15, 2024, at 5:20 p.m. ET. H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York on Monday...
Meritage Homes Announces Pricing of Convertible Senior Notes
Meritage Homes Announces Pricing of Convertible Senior Notes SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Meritage Homes Corporation (NYSE: MTH, “Meritage” or the “Company”), the fifth-largest homebuilder in the U.S., today announced the pricing of $500 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2028 (the “notes”). The Company also granted the initial purchasers of the notes a 13-day option to purchase up to $75 million of aggregate principal amount of additional notes. The sale of the notes is expected to settle on May 9, 2024, subject to customar...
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024 Eight presentations showcase the broad applicability of HSC gene therapy to address rare neurometabolic diseases and beyond TOKYO, LONDON and BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced four oral and four poster presentations from across its hematopoietic stem cell (HSC) gene therapy platform will be featured at the 27th Annual Meeting of the American Society ...
Arvinas Reports First Quarter 2024 Financial Results and Provides Corp...
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update – Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for up to $1.01 ...
JLT Mobile Computers AB (publ) publishes interim report for January–Ma...
JLT Mobile Computers AB (publ) publishes interim report for January–March 2024 Växjö, Sweden, 7 May 2024 * * * , a leading supplier of rugged computers for demanding environments, publishes its interim report for the period January–March 2024 today. Summary of key figures Order intake 33.7 MSEK (34.0)Net sales 37.7 MSEK (49.9)Operating profit 0.8 MSEK (2.6)Profit after taxes 0.5 MSEK (2.2) In short The order intake for the first quarter ended at 34 million SEK, the same level as the first quarter of the previous year.Continued weak demand in target markets, especially transp...
Neumora Therapeutics Reports First Quarter 2024 Financial Results and ...
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study initiations planned in second quarter of 2024, including Phase 2 study in bipolar depression with navacaprant and Phase 1b study in Alzheimer's disease agitation with NMRA-511 Strong financial position with $423.0 million in cash, cash equivalents and marketable securities expected to support operations into 2026, providing runway through multi...
Harvard Bioscience Announces First Quarter 2024 Financial Results
Harvard Bioscience Announces First Quarter 2024 Financial Results Strong gross margin performance and focus on efficiency to support ongoing investments in growth HOLLISTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2024. Jim Green, Chairman and CEO, said, “As expected, our first quarter revenues reflect ongoing market headwinds, especially in APAC, amplified by a strong prior year comparison. Despite these headwinds, we were pleased to deliver gross margins of ...
GlobalFoundries Reports First Quarter 2024 Financial Results
GlobalFoundries Reports First Quarter 2024 Financial Results MALTA, N.Y., May 07, 2024 (GLOBE NEWSWIRE) -- GlobalFoundries Inc. (GF) (Nasdaq: GFS) today announced preliminary financial results for the first quarter ended March 31, 2024. Key First Quarter Financial Highlights Revenue of $1.549 billionGross margin of 25.4% and Non-IFRS gross margin(1) of 26.1%Operating margin of 9.5% and Non-IFRS operating margin(1) of 12.1%Net income of $134 million and Non-IFRS net income(1) of $174 millionNon-IFRS EBITDA(1) of $577 millionCash, cash equivalents and marketable securities of $4.2 billio...
JLT Mobile Computers AB (publ) släpper delårsrapport för perioden janu...
JLT Mobile Computers AB (publ) släpper delårsrapport för perioden januari–mars 2024 Växjö, Sverige, 7:e maj 2024 * * * , ledande leverantör av stryktåliga datorer för krävande miljöer, släpper idag delårsrapport för perioden januari–mars 2024. Periodens resultat i korthet Orderingång 33,7 MSEK (34,0)Omsättning 37,7 MSEK (49,9)Rörelseresultat 0,8 MSEK (2,6)Resultat efter skatt 0,5 MSEK (2,2) Kortsummering Orderingången för första kvartalet slutade på 34 MSEK, samma nivå som första kvartalet föregående år Fortsatt svag efterfrågan på JLT:s målmarknader, speciellt inom transpo...
REMINDER -- Stella-Jones’ Annual and Special Meeting of Shareholders a...
REMINDER -- Stella-Jones’ Annual and Special Meeting of Shareholders and First-Quarter Results Conference Call MONTRÉAL, May 07, 2024 (GLOBE NEWSWIRE) -- The Annual and Special Meeting of Shareholders of Stella-Jones Inc. will be held as a hybrid meeting: On Wednesday, May 8, 2024, at 10:00 AM Eastern Daylight TimeIn-person at :1250 René-Lévesque Blvd. West, suite 3610Montréal, Québec Or virtually by webcast at: Password : stella2024(Password is case-sensitive) Management will be available to speak with the media immediately following the meeting. Registered shareholders and duly appoi...
Nurix Therapeutics to Participate in RBC Capital Markets Global Health...
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference at 9:30-9:55 a.m. ET, on Tuesday, May 14, 2024. The event will be w...
RAPPEL -- Assemblée annuelle et extraordinaire des actionnaires et tél...
RAPPEL -- Assemblée annuelle et extraordinaire des actionnaires et téléconférence du premier trimestre de Stella-Jones MONTRÉAL, 07 mai 2024 (GLOBE NEWSWIRE) -- L’assemblée annuelle et extraordinaire des actionnaires de Stella-Jones Inc. aura lieu en format hybride : Mercredi le 8 mai 2024 à 10h00 (Heure avancée de l’Est) En personne :1250 boulevard René-Lévesque Ouest, bureau 3610 Montréal, QuébecOu virtuellement par webdiffusion :Mot de passe : stella2024 (Le mot de passe est sensible à la casse) Les membres de la direction seront disponibles pour rencontrer les journalistes immédiat...
Airboss Announces Proposed Settlement of Class Action
Airboss Announces Proposed Settlement of Class Action NEWMARKET, Ontario, May 07, 2024 (GLOBE NEWSWIRE) -- AirBoss of America Corp. (TSX: BOS) (OTCQX: ABSSF) (the “Company” or “AirBoss”) today announced that, subject to court approval, it has reached a settlement of the class action lawsuit pending against the Company in Canada. As previously disclosed in the Company’s December 16, 2022 press release, a statement of claim was issued (under the Class Proceedings Act, 1992) in the Ontario Superior Court of Justice (the “Court”) against AirBoss and several named officers. The proceedings ...
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase ...
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102 VERVE-102 is an investigational in vivo base editing medicine designed to permanently inactivate the PCSK9 gene in the liver to durably reduce blood low-density lipoprotein cholesterol Heart-2 enrolling patients with heterozygous familial hypercholesterolemia or premature coronary artery disease BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines...
Cronos Enters United Kingdom Cannabis Market
Cronos Enters United Kingdom Cannabis Market TORONTO, May 07, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) announced today that it is expanding its medical brand, PEACE NATURALS, into the United Kingdom market with its first shipment of cannabis flower to GROW® Pharma, a leading distributor of prescribed medicinal cannabis products in the UK. Cronos will provide high-quality premium cannabis products, which have become synonymous globally with the PEACE NATURALS® brand, to patients in the UK through this partnership. The Company’s inve...
Applied Therapeutics to Present at the 2024 RBC Capital Markets Global...
Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024 at 4:35 p.m. ET in New York, New York. A live webcast for this event will be accessible on the Event...
American Shared Hospital Services Announces First Quarter 2024 Earning...
American Shared Hospital Services Announces First Quarter 2024 Earnings Conference Call SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a conference call to discuss its first quarter 2024 financial results on Tuesday, May 14th at 4:30 pm ET / 1:30 pm PT. The first quarter 2024 financial results press release will be issued at the market close...
Red Cat Launches Robotics and Autonomous Systems Consortium to Bridge ...
Red Cat Launches Robotics and Autonomous Systems Consortium to Bridge Critical UAS Technology Gaps for Warfighters SAN JUAN, Puerto Rico, May 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RCAT) (“Red Cat”), a drone technology company integrating robotic hardware and software for military, government, and commercial operations, today announced the formation of the (RFI). RFI is an independent, industry-wide consortium of robotics and autonomous systems (RAS) partners dedicated to putting the most advanced and interoperable uncrewed aircraft systems into the hands of warfighters. Anchored by R...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.